Article
Multidisciplinary Sciences
Fang Deng, Xiuan Gao, Limian Xu, Weijie Li, Zubing Mei, Caijun Xie
Summary: The purpose of this study is to provide the latest evidence on the risk of adverse obstetric and perinatal outcomes in female survivors of childhood or adolescent cancer.
Article
Multidisciplinary Sciences
Fang Deng, Xiuan Gao, Limian Xu, Weijie Li, Zubing Mei, Caijun Xie
Summary: This study aims to provide the up-to-date evidence on the risk of adverse obstetric and perinatal outcomes in female survivors of childhood or adolescent cancer through a meta-analysis. The research will be conducted and reported following appropriate guidelines and tools, and heterogeneity will be explored through subgroup analysis based on multiple study characteristics.
Article
Multidisciplinary Sciences
Joo Eun Shin, Su Jin Lee, Amal Gharbi, In Duk Jung, Yeong Min Park
Summary: Psoriasis, a chronic autoimmune disease with limited treatment options, can be alleviated by the therapeutic potential of a novel drug IOX1, which targets genetic factors and reduces inflammation in psoriatic mice. This indicates the remedial effects of IOX1 on psoriasis and its potential as a therapeutic compound.
Review
Immunology
Jin Bu, Ruilian Ding, Liangjia Zhou, Xiangming Chen, Erxia Shen
Summary: Psoriasis is a chronic autoimmune inflammatory disease that affects not only the skin, but also other systems of the body and mental health. Recent studies have shown associations between psoriasis and various systemic diseases, including the skin system, reproductive system, and oral and ocular systems, as well as mental health diseases, due to a shared immune-inflammatory mechanism. This review summarizes epidemiological evidence from the past 5 years, supporting the association between psoriasis and important and/or newly reported systemic diseases, aiming to improve the management of people with psoriasis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Sofia Passaponti, Leonardo Ermini, Giulia Acconci, Filiberto Maria Severi, Roberta Romagnoli, Santina Cutrupi, Marinella Clerico, Gisella Guerrera, Francesca Ietta
Summary: This study demonstrates the influence of late pregnancy on the balance between RANKL and OPG in women with multiple sclerosis (MS), and identifies the placenta as an important source of homodimeric OPG. Placental OPG suppresses the mRNA expression of CCL20 and affects the recruitment of Th17 cells. Therefore, placental OPG may play a crucial role in the beneficial effects of late pregnancy on MS, and could potentially be used for the development of new and more effective therapeutic approaches.
Review
Rheumatology
Yasser El Miedany, Deborah Palmer
Summary: The emergence of reproductive rheumatology has improved clinical care for autoimmune rheumatic disease patients and paved the way for specialized pregnancy services within rheumatology practice. While there is extensive literature on pregnancy, lactation, and birth outcomes for women, there is a lack of focus on male sexual health and outcomes among inflammatory arthritis patients. Challenges such as decreased ability to conceive, impaired fertility, erectile dysfunction, and other sexual problems have been raised by male patients with autoimmune rheumatic diseases.
CLINICAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Timothy S. H. Kwok, Mitchell Sutton, Daniel Pereira, Richard J. Cook, Vinod Chandran, Nigil Haroon, Robert D. Inman, Dafna D. Gladman
Summary: Isolated axial PsA and AS with psoriasis are relatively uncommon. HLA-B*27 positivity is associated with isolated axial PsA and may predict the development of peripheral disease. Isolated axial PsA is associated with better functional status. Isolated axial PsA appears clinically distinct from isolated axial AS with psoriasis.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Alba Boix-Amoros, Michelle H. Badri, Julia Manasson, Rebecca B. Blank, Rebecca H. Haberman, Andrea L. Neimann, Parvathy Girija, Anthony Jimenez Hernandez, Adriana Heguy, Sergei Koralov, Richard Bonneau, Jose C. Clemente, Jose U. Scher
Summary: This study investigated the differences in cutaneous microbiome between healthy individuals and patients with psoriasis and psoriatic arthritis. The results showed significant differences in diversity and bacterial composition between healthy skin and psoriatic skin, both lesional and non-lesional. Bacterial biomarkers were also identified that could potentially aid in predicting disease progression from psoriasis to psoriatic arthritis.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Pharmacology & Pharmacy
Carla Carnovale, Francesca Parisi, Vera Battini, Alice Zavatta, Stefania Cheli, Dario Cattaneo, Michele Gringeri, Giulia Mosini, Greta Guarnieri, Gianluca Cammarata, Irene Cetin
Summary: Women of childbearing age are significantly affected by autoimmune disorders. The increasing use of biological agents has improved treatment outcomes, especially for pregnant women. However, there is still incomplete information on the risks of using these agents during pregnancy.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Food Science & Technology
Paulo Cesar Trindade da Costa, Evandro Leite de Souza, Diego Cabral Lacerda, Jose Patrocinio Ribeiro Cruz Neto, Ludmilla Christine Silva de Sales, Cristiane Cosmo Silva Luis, Paula Brielle Pontes, Marinaldo Pacifico Cavalcanti Neto, Jose Luiz de Brito Alves
Summary: Supplementing with quercetin during pregnancy and lactation can reduce the risk of maternal cardio-metabolic disorders and improve cardiovascular health in offspring. Epigenetic mechanisms involving AMPK, NF-κB, and PI3K pathways may be associated with these changes.
Article
Peripheral Vascular Disease
Sukainah Al Khalaf, Lucy C. C. Chappell, Ali S. S. Khashan, Fergus P. P. McCarthy, Eilis J. O'Reilly
Summary: There is a strong association between chronic hypertension and the risk of cardiovascular disease (CVD) in mothers, especially those with adverse pregnancy outcomes (APOs). This risk can lead to premature CVD, thus intervention programs targeting these high-risk groups might reduce their risk of subsequent CVD.
Article
Immunology
Rishabh Chaudhary, Ajay Prasad, Vipul Agarwal, Mujeeba Rehman, Anand Kumar, Arjun Singh Kaushik, Siddhi Srivastava, Sukriti Srivastava, Vikas Mishra
Summary: This study validates the role of chronic stress in the aggravation of rheumatoid arthritis and psoriasis. The findings suggest that a prolonged 8-week exposure to unpredictable stress leads to worsened symptoms and increased inflammatory response in rats, which are associated with these autoimmune diseases.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Endocrinology & Metabolism
Xinyi Sun, Yang Liu, Yunhui Tang, Hongying Yu, Min Zhao, Qi Chen
Summary: The study found that 14% of women with a history of cesarean scar pregnancy did not have a subsequent pregnancy after unprotected sexual intercourse for more than two years. Light menstrual bleeding after treatment may be associated with this adverse effect, but further investigation with a larger sample size is needed.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Hilary K. Brown, Kathryn Barrett, Natalie Scime
Summary: This review examines the association between perinatal mental illness and maternal autoimmune disease, highlighting the shared characteristics and bidirectional relationship between the two. Further research is needed to determine the specific diagnosis, severity, and timing of perinatal mental illness and autoimmune disease, as well as the relative importance of perinatal versus non-perinatal mental illness. This research could have significant implications for the prevention, treatment, and follow-up of perinatal mental illness.
FRONTIERS IN NEUROENDOCRINOLOGY
(2022)
Article
Medicine, Research & Experimental
Aeri Park, Tae-Hwe Heo
Summary: IL-17A is a crucial pro-inflammatory cytokine in autoimmune diseases, which can be inhibited by fenofibrate, a small molecule drug. Fenofibrate regulates autophagy and exerts anti-inflammatory effects, suggesting its potential as a therapeutic for psoriasis and other autoimmune diseases.
Article
Dermatology
Federico Pirro, Giacomo Caldarola, Andrea Chiricozzi, Sara Tambone, Marco Mariani, Laura Calabrese, Dario Francesco D'Urso, Clara De Simone, Ketty Peris
Summary: This study investigated the impact of the COVID-19 pandemic on a cohort of Italian psoriatic patients treated with biologics. It found that discontinuation of biologics may lead to worsening of psoriasis, and psychological status also directly influences the clinical course of the disease.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Biotechnology & Applied Microbiology
Andrea Chiricozzi, Niccolo Gori, Martina Maurelli, Paolo Gisondi, Giacomo Caldarola, Clara De Simone, Ketty Peris, Giampiero Girolomoni
Summary: Selective IL-13 inhibitors have shown clinical efficacy against AD, suggesting that IL-13 plays a central role in AD pathogenesis. However, the therapeutic value and place-in-therapy of IL-13 inhibitors are not fully defined. This review article describes strengths and limitations of different anti-IL-13 agents used to treat AD that might be useful in driving treatment decision.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2022)
Article
Dermatology
Giacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, Laura Calabrese, Marta Grimaldi, Gaia Moretta, Gianluca Pagnanelli, Ruslana Gaeta Shumak, Marina Talamonti, Lorenzo Tofani, Sabatino Pallotta, Ketty Peris, Concetta Potenza, Clara De Simone, Elena Campione
Summary: The efficacy and safety of tildrakizumab were evaluated in a real-life setting for patients with moderate-to-severe psoriasis over a 28-week treatment period. The results showed that tildrakizumab had high efficacy and a favorable safety profile, regardless of patient- and disease-related factors.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Giacomo Caldarola, Arianna Zangrilli, Nicoletta Bernardini, Mauro Bavetta, Clara De Simone, Dario Graceffa, Claudio Bonifati, Sara Faleri, Domenico Giordano, Marco Mariani, Adriana Micheli, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Alessia Provini, Antonio Richetta, Ketty Peris, Luca Bianchi
Summary: This study aimed to evaluate the efficacy and safety of risankizumab in patients with moderate-to-severe psoriasis. The results showed that risankizumab demonstrated high efficacy and a favorable safety profile over a 52-week period, regardless of patient- and disease-related factors.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Emanuele Scala, Robert Kaczmarczyk, Alexander Zink, Anna Balato
Summary: This study investigated the relationship between global characteristics of psoriasis patients and impairment of their quality of life. The study found that living in Southern Italy, depression, psoriatic arthritis, and psoriasis localized on the face, intertriginous, palmoplantar, trunk, and scalp regions had a large effect on patients' quality of life. Phototherapy and non-biological systemic therapies had a moderate effect. Mild psoriasis, living in social housing, and isolated involvement of scalp psoriasis had a small effect. Mild psoriasis and certain biological therapies including anti-IL-12/23, anti-IL-17, and anti-TNF-alpha were positively associated with no impairment of life quality.
DERMATOLOGIC THERAPY
(2022)
Letter
Dermatology
G. Avallone, F. Cavallo, C. Astrua, G. Caldarola, C. Conforti, C. De Simone, N. di Meo, A. di Stefani, G. Genovese, C. A. Maronese, A. V. Marzano, R. Parente, P. Quaglino, G. Roccuzzo, F. Tassone, I. Zalaudek, R. Senetta, S. Ribero
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Giacomo Caldarola, A. Chiricozzi, M. Megna, P. Dapavo, A. Giunta, M. Burlando, P. Malagoli, V Dini, M. Mariani, G. Fabbrocini, P. Quaglino, L. Bianchi, A. Parodi, K. Peris, C. De Simone
Summary: This study aimed to evaluate the 3-year drug survival of ixekizumab in the treatment of moderate-to-severe plaque psoriasis patients. It found that ixekizumab is characterized by long-term effectiveness and good safety profile, not influenced by several clinical factors.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Dermatology
Giacomo Caldarola, Eleonora De Luca, Marco Mariani, Andrea Chiricozzi, Ketty Peris, Clara De Simone
Summary: This study conducted a retrospective observational study on the use of methotrexate in patients with psoriasis. It found that while the drug has some effectiveness in long-term treatment, the drug survival rate is lower compared to biological treatments.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Alexandra M. G. Brunasso, Martina Burlando, Fabrizio Amoruso, Luisa Arancio, Giovanna Malara, Raffaella Manzo, Maria Antonia Montesu, Giacomo Caldarola
Summary: Psoriasis is a chronic inflammatory disease that affects 29.5 million people worldwide, causing negative impact on quality of life when it affects specific areas. Risankizumab, a humanized monoclonal antibody, effectively treats moderate to severe psoriasis by targeting interleukin-23. Our real-world cases demonstrate the efficacy of risankizumab in improving clinical manifestations and relieving symptoms, without safety concerns.
Article
Dermatology
Giacomo Caldarola, Eleonora De Luca, Mauro Bavetta, Nicoletta Bernardini, Annunziata Dattola, Clara De Simone, Dario Graceffa, Claudio Bonifati, Paola Tribuzi, Domenico Giordano, Marco Mariani, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Alessia Provini, Antonio Richetta, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Ketty Peris
Summary: This study evaluated the long-term effectiveness and drug survival rate of risankizumab in patients with moderate to severe psoriasis. The results showed that over a period of 2 years, risankizumab demonstrated sustained clinical response and a favorable safety profile in psoriatic patients.
DERMATOLOGIC THERAPY
(2023)
Article
Pharmacology & Pharmacy
Giulia Coscarella, Dalma Malvaso, Maria Mannino, Giacomo Caldarola, Barbara Fossati, Clara De Simone, Andrea Chiricozzi, Ketty Peris
Summary: Psoriasis is a chronic inflammatory skin disease, with plaque psoriasis being the most common form. Understanding the role of the IL-23/IL-17 axis has led to a new approach in treating the disease. The development of deucravacitinib, an oral TYK2 inhibitor, as a therapeutic option for moderate-to-severe psoriasis is based on pre-clinical and early phase clinical studies.
EXPERT OPINION ON DRUG DISCOVERY
(2023)
Article
Dermatology
Andrea Chiricozzi, Giacomo Dal Bello, Niccolo Gori, Lucia Di Nardo, Donatella Schena, Giacomo Caldarola, Martina Maurelli, Clara De Simone, Giampiero Girolomoni, Ketty Peris
Summary: This study aimed to identify predictive factors for dose spacing or treatment withdrawal in patients receiving dupilumab for atopic dermatitis. The presence of non-cutaneous atopic manifestations, prurigo nodularis phenotype, and younger age at treatment initiation were confirmed as strong predictors. These findings contribute to defining the patient profile that can maintain therapeutic response after dose spacing or treatment withdrawal.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Letter
Dermatology
L. Quattrini, G. Caldarola, G. M. Falco, L. M. Pinto, K. Peris
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Dermatology
Francesco Bellinato, Paolo Gisondi, Anna Balato, Giacomo Caldarola, Edoardo Cammarata, Elena Campione, Andrea Carugno, Andrea Conti, Monica Corazza, Paolo Dapavo, Annunziata Dattola, Vito Di Lernia, Massimo Gasperini, Salvatore Panduri, Francesca Prignano, Francesca Satolli, Enzo Spisni, Giampiero Girolomoni
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Giacomo Caldarola, Gennaro Marco Falco, Laura Calabrese, Alessandra D'Amore, Andrea Chiricozzi, Marco Mariani, Gerardo Palmisano, Clara De Simone, Ketty Peris
Summary: Treatment of palmoplantar psoriasis is challenging, and biologic drugs provide longer persistence in treatment compared to non-biologics.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)